surmount-1 trial tirzepatide weight loss nondiabetic non-diabetic obesity Effect of in trial. (BMI: body mass index; CI: surmount-1 trial tirzepatide – Tirzepatide after intensive lifestyle intervention – Tirzepatide after intensive lifestyle intervention

That does not mean one medication is automatically right for every patient

Unmeasured factors associated with a better response to semaglutide treatment (i.e., greater weight loss), such as more favorable social determinants of health, could decrease the likelihood of MACE outcomes

If you experience nausea, dizziness, or digestive discomfort that disrupts your day or sleep, let your physician know

If you are already taking glucose-lowering medications such as metformin, insulin, or sulfonylureas, discuss it with your doctor to reduce the risk of hypoglycemia

Clinical trials measured results over 72 weeks, so this is generally considered a long-term treatment rather than a quick fix

Similar side effects were observed with the D/D antagonist ecopipam